Source link : https://www.newshealth.biz/health-news/bimekizumab-offers-durable-and-consistent-benefits-in-hs/
AMSTERDAM — The monoclonal antibody bimekizumab (Bimzelx) achieves significant and clinically meaningful improvements in moderate to severe hidradenitis suppurativa (HS) that are maintained well beyond the initial 1-year clinical trial treatment period, according to new data from an open-label extension period. “Efficacy and health-related quality-of-life outcomes were maintained through 2 years of treatment,” study presenter […]
Author : News Health
Publish date : 2024-11-04 11:41:50
Copyright for syndicated content belongs to the linked Source.
inHealth